^ WATERTOWN, Massachusetts, and GOSSELIES, Belgium, March 05, 2024 (GLOBE
NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches
Clinical research company pioneering the
Research and development of a new generation of immuno-oncology
provides therapeutics for patients has a poster presentation today
announced preclinical data on EOS-984, the first small molecule
Antagonist of its class, which relies on the equilibrative nucleoside transporter 1
(ENT1). The presentation will take place at the annual meeting of the American
Association for Cancer Research (AACR), die vom 5. bis 10. April 2024 in San
Diego, California.
Details about the poster presentation
Abstract 734,?Inhibition of equilibrative nucleoside transporter 1 relieves
intracellular adenosine-mediated immune suppression” (Hemmung des Equilibrativen
Nucleoside transporter 1 alleviates intracellular adenosine-mediated
immunosuppression)
* Sitzung: Experimental and Molecular Therapeutics: Tumor Microenvironment
(Experimental and Molecular Therapeutics: Tumor Microenvironment)
* Date and Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
* Ort: Poster Section 29
Über iTeos Therapeutics, Inc.
iTeos Therapeutics is a biopharmaceutical company in the field of
clinical research, pioneering research and development
a new generation of immuno-oncology therapeutics for patients
performs. Based on a deep understanding of tumor immunology and
iTeos Therapeutics is developing new immunosuppressive signaling pathways
Product candidates that have the potential to enhance the immune response against cancer
to restore. The company’s innovative pipeline includes three
Clinical phase programs based on novel, validated
Target immuno-oncological signaling pathways and with optimized pharmacological ones
Features developed for improved clinical outcomes include
the TIGIT/CD226 axis and the adenosine signaling pathway. iTeos Therapeutics has its
Headquarters in Watertown, MA and a research center in Gosselies, Belgium.
About EOS-984
EOS-984 is the first small molecule drug in its class targeting the
Equilibrative nucleoside transporter 1 (ENT1) is aimed at immunosuppressive
Effect of adenosine to inhibit and proliferation of immune cells
to restore. The therapeutic candidate has the potential to be strong
to completely reverse the immunosuppressive effect of adenosine on T and B cells
and is in Phase I development.
Publication of information on the Internet
iTeos Therapeutics routinely publishes information intended for investors
could be important in the “Investors” section of his website
at www.iteostherapeutics.com. The company encourages investors and
potential investors to visit the website regularly for important information
Get information about iTeos Therapeutics.
Forward-Looking Statements
This press release contains forward-looking statements. All statements that
are not based exclusively on historical facts, are future-oriented
Testify. Words like?believe”,?anticipate”,?plan”,?expect”,?become”,
“can”, “intend”, “prepare”, “see”, “potential”, “possible” and
Similar expressions are intended to identify forward-looking statements. To this
Forward-looking statements include statements about potential benefits
of product candidates in the Company’s pipeline, including EOS-984.
These forward-looking statements involve risks and uncertainties
connected, many of which are outside the control of iTeos. The
actual results may vary due to these risks and uncertainties
differ materially from those indicated in these forward-looking statements or
implied results differ. The known risk factors include:
following: iTeos could be due to challenges and uncertainties
with product research and development as well as the production of biologics
associated with facing unforeseen costs or cash
output faster or slower than currently expected; the success of preclinical
Tests and early clinical trials do not ensure later clinical trials
Studies will be successful, and early results from a clinical trial
do not necessarily predict the final results; the data for
our product candidates may not be sufficient to meet regulatory requirements
To obtain approval for later phase studies or products
market; iTeos may not be able to fulfill its business plans
to implement, including compliance with the expected or planned
Regulatory, research and clinical milestones and timelines
development plans and the market launch of its product candidates
various reasons, some of which are beyond the control of iTeos
including possible financial and other restrictions
Company resources, manufacturing limitations, the
may not be able to be foreseen or remedied in a timely manner,
negative developments in the field of immuno-oncology, such as: b.
adverse events or disappointing results, including related to
Therapies from competitors and decisions from regulatory authorities and courts
or authorities, such as B. U.S. Patent and Trademark Office Decisions Regarding
to patents covering our product candidates; and the risks involved
under the heading “Risk Factors” in iTeos’ Quarterly Report on Form 10-Q
for the quarter ended September 30, 2023, which is included
filed with the Securities and Exchange Commission (SEC), as well as in others
The company’s SEC filings you should take note of.
We caution investors not to place undue reliance on anything contained in this press release
any forward-looking statements contained herein. iTeos doesn’t cover any
Obligation to publicly update its forward-looking statements,
unless required by law.
For further information please contact:
Investor contact:
Carl Mauch
iTeos Therapeutics, Inc.
Media contact:
°